Advanced Technologies - National Center for Image Guided Therapy (AT-NCIGT)

先进技术 - 国家影像引导治疗中心 (AT-NCIGT)

• 批准号: 10326345
• 负责人: CLARE M TEMPANY
• 金额: $ 139.14万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-06 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10326345
• 关键词: 3-Dimensional; Acute; Algorithms; Architecture; Atlas of Cancer Mortality in the United States; Augmented Reality; Biomedical Research; Biopsy Specimen; Blood; Brain; Brain Neoplasms; Cells; Characteristics; Communities; Complex; Computer Vision Systems; Computer software; Conventional Surgery; Data; Development; Devices; Diffusion; Discipline; Disease; Early Diagnosis; Effectiveness; Evolution; Foundations; Goals; Health Care Research; Heterogeneity; Histopathology; Image; Imaging Device; Imaging Techniques; Immunotherapy; Individual; Information Retrieval; Infrastructure; Intervention; Interventional radiology; Knowledge; Lesion; Longitudinal Studies; Lung; Magnetic Resonance; Magnetic Resonance Imaging; Malignant neoplasm of prostate; Medical; Medicine; Metabolic Marker; Metabolism; Metadata; Methods; Microscopic; Mission; Modeling; Molecular; Morphology; Nanotechnology; Navigation System; Needles; Neoplasm Metastasis; Operating Rooms; Operative Surgical Procedures; Patient Care; Patient-Focused Outcomes; Pattern; Physiologic pulse; Procedures; Prostate; Radiation Oncology; Recurrence; Research; Resistance; Resolution; Retrieval; Risk Assessment; Sampling; Services; Signal Transduction; Source; Specimen; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Speed; Supervision; T2 weighted imaging; Technology; Testing; Time; Tissue Sample; Tissue imaging; Tissues; Visualization; base; big-data science; biomedical resource; brain surgery; cancer care; cancer heterogeneity; cancer imaging; cancer therapy; data curation; data integration; deep learning; design; digital; image guided; image guided therapy; image registration; imaging facilities; imaging modality; improved; in vivo; in vivo monitoring; innovation; ion mobility; learning strategy; machine learning algorithm; mass spectrometer; mass spectrometric imaging; metabolic imaging; microdevice; neoplastic; new technology; novel; novel strategies; overtreatment; personalized cancer therapy; personalized medicine; precision medicine; prostate biopsy; protocol development; response; surgery outcome; technology research and development; tissue oxygenation; tool; trait; tumor; tumor heterogeneity; tumor hypoxia

ABSTRACT: The intersection of healthcare and biomedical research is at an inflection point with the convergence of the digital revolution, advances in imaging, nanotechnology, big data science, and precision or personalized medicine. There is a wealth of meaningful, but complex information that could be extracted from imaging data but is not optimally utilized for patient care. Cancer care exemplifies the current challenges which include early detection, accurate distinction of pre- neoplastic and neoplastic lesions, prediction of tumor aggressiveness, determining infiltrative tumor margins during surgical treatment, tracking tumor evolution/ metastasis pattern, recurrence, and potential acquired resistance to treatments over time. Major strides have been made in the personalization of cancer therapies such as immunotherapy, but the availability of specific, relevant, and timely medical data and information is of critical importance to realizing the full potential of precision medicine. Nowhere is this more acutely evident than during interventions in the operating and procedure rooms. Novel methods of image guidance, data integration, information extraction, and knowledge transfer are needed to enable clinicians to fully leverage the information available, especially before, during and after invasive procedures. We are excited to re-submit a proposal for a new P41 biomedical resource center (BTRC) called Advanced Technologies for NCIGT(AT-NCIGT) with 3 TRDs, 10 new collaborative and 10 new service projects, all of which aim to investigate develop and disseminate new technologies for image guided therapy (IGT). The 3 components are Imaging Cancer Heterogeneity for IGT, Deep Learning for IGT and Intraoperative devices for IGT. These new technologies alone and in combinations will allow for greater understanding of disease state, treatment guidance, integration/navigation and in-vivo monitoring of tissue responses and improve the precision of invasive procedures. Thus the overall goal of this proposal is to investigate, develop and disseminate novel technologies for extracting new tissue characteristics (technology research and development core TRD 1: Imaging cancer heterogeneity; analyze them and make them available through state-of-the-art algorithmic and data curation approaches (Deep Learning TRD 2); and enable precise tissue sampling surgical navigation and in-vivo tissue response through the results of novel Intraoperative devices (Intraoperative devices for IGT: TRD 3). In order to effectively disseminate all this new knowledge we have 10 new collaborative and 10 new service projects and will share these novel tools through our established mechanisms, from current BTRC- National Center for Image Guided Therapy (NCIGT), which continues to be dedicated to the innovating for IGT into interventional radiology, surgery, radiation oncology, and procedure-based medicine.

摘要：医疗保健与生物医学研究的交叉正处于一个拐点